DrugPatentWatch Database Preview

Lorlatinib - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for lorlatinib and what is the scope of lorlatinib patent protection?

Lorlatinib is the generic ingredient in one branded drug marketed by Pfizer Inc and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Lorlatinib has fifty patent family members in forty-two countries.

One supplier is listed for this compound.

Summary for lorlatinib

International Patents:	50
US Patents:	1
Tradenames:	1
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	42
Clinical Trials:	12
Patent Applications:	41
DailyMed Link:	lorlatinib at DailyMed

Synonyms for lorlatinib

(10R)-7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-2H-4,8-methenopyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile

(10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-4,8-methenopyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile

(10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-H][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile

1454846-35-5

2641AH

2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-

4cli

4clj

7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile

AK175603

AKOS027250753

BC600707

BCP10287

BDBM50018830

CHEMBL3286830

CS-3983

D11012

DB12130

EX-A828

FT-0700455

GTPL7476

HY-12215

J-690185

KB-334037

KS-00000T6C

Loratinib

Lorbrena (TN)

lorlantinib

Lorlatinib (JAN/USAN/INN)

Lorlatinib [USAN:INN]

Lorlatinib,PF-06463922

MFCD28144520

MolPort-035-789-724

NCGC00386417-02

NCGC00386417-13

OSP71S83EU

PF 06463922

PF-06463922

PF-6463922

PF06463922(Lorlatinib)

s7536

SCHEMBL15261807

UNII-OSP71S83EU

ZINC98208524

US Patents and Regulatory Information for lorlatinib

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer Inc	LORBRENA	lorlatinib	TABLET;ORAL	210868-002	Nov 2, 2018		RX	Yes	Yes
Pfizer Inc	LORBRENA	lorlatinib	TABLET;ORAL	210868-001	Nov 2, 2018		RX	Yes	No
Pfizer Inc	LORBRENA	lorlatinib	TABLET;ORAL	210868-001	Nov 2, 2018		RX	Yes	No			Y	Y
Pfizer Inc	LORBRENA	lorlatinib	TABLET;ORAL	210868-002	Nov 2, 2018		RX	Yes	Yes			Y	Y
Pfizer Inc	LORBRENA	lorlatinib	TABLET;ORAL	210868-001	Nov 2, 2018		RX	Yes	No

International Patents for lorlatinib

Country	Patent Number	Estimated Expiration
Japan	2016041709
Taiwan	I476199
Portugal	2822953
Spain	2621220
Taiwan	201350484